Jove
Visualize
Contact Us

Related Concept Videos

Heart Failure I: Introduction01:27

Heart Failure I: Introduction

Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Contemporary Use of Oral Antithrombotic Agents: Focus on Dual and Triple Therapeutic Approaches.

Pharmacotherapy·2017
Same author

The role of academic pharmacy in tobacco cessation and control.

American journal of pharmaceutical education·2013
Same author

Intrapericardial triamcinolone for acute pericarditis after electrophysiologic procedures.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·2010
Same author

Cost-effectiveness analysis of anticoagulation strategies in non-ST-elevation acute coronary syndromes.

The Annals of pharmacotherapy·2009
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: May 29, 2026

Implantation of an Isoproterenol Mini-Pump to Induce Heart Failure in Mice
05:08

Implantation of an Isoproterenol Mini-Pump to Induce Heart Failure in Mice

Published on: October 3, 2019

Drug-induced heart failure.

Carleton B Maxwell1, Antoine T Jenkins

  • 1Department of Pharmacy, Carolinas Medical Center, 1000 Blythe Boulevard, Charlotte, NC 28232, USA. carleton.maxwell@carolinashealthcare.org

American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists
|September 21, 2011
PubMed
Summary
This summary is machine-generated.

Many medications can cause or worsen heart failure (HF). Healthcare providers should monitor patients for cardiovascular effects, especially when using drugs linked to HF or other cardiac issues.

More Related Videos

Induction and Phenotyping of Acute Right Heart Failure in a Large Animal Model of Chronic Thromboembolic Pulmonary Hypertension
07:41

Induction and Phenotyping of Acute Right Heart Failure in a Large Animal Model of Chronic Thromboembolic Pulmonary Hypertension

Published on: March 17, 2022

Related Experiment Videos

Last Updated: May 29, 2026

Implantation of an Isoproterenol Mini-Pump to Induce Heart Failure in Mice
05:08

Implantation of an Isoproterenol Mini-Pump to Induce Heart Failure in Mice

Published on: October 3, 2019

Induction and Phenotyping of Acute Right Heart Failure in a Large Animal Model of Chronic Thromboembolic Pulmonary Hypertension
07:41

Induction and Phenotyping of Acute Right Heart Failure in a Large Animal Model of Chronic Thromboembolic Pulmonary Hypertension

Published on: March 17, 2022

Area of Science:

  • Cardiology
  • Pharmacology
  • Internal Medicine

Background:

  • Medications are essential in modern healthcare but can pose risks.
  • Heart failure (HF) is a significant public health concern.
  • Understanding drug-induced HF is crucial for patient safety.

Purpose of the Study:

  • To review published evidence on drugs causing or exacerbating heart failure (HF).
  • To discuss precautions and management strategies for drug-induced HF in clinical practice.

Main Methods:

  • A comprehensive literature search was conducted.
  • Reports of new-onset HF and HF exacerbations linked to medication use were identified.
  • Data from controlled clinical trials, postmarketing surveillance, and observational studies were analyzed.

Main Results:

  • Established HF causes include thiazolidinediones and older chemotherapy agents.
  • Numerous other drugs, including tyrosine kinase inhibitors and biological response modifiers, are implicated.
  • Newer drugs like dronedarone, itraconazole, trastuzumab, lapatinib, and bevacizumab have been linked to serious cardiac effects.

Conclusions:

  • A wide array of medications are associated with drug-induced HF.
  • Patients on implicated medications require vigilant monitoring for cardiovascular adverse effects.
  • Early detection and management are key to mitigating risks.